Since inhibition of the AKT/mTOR pathway leads to downregulation of BRCA1/2 and homologous recombination and olaparib activates AKT/mTOR signaling15,19,45, the combination of olaparib and ONC206 may have a synergistic effect in inhibiting tumor growth in EC via dual inhibition of the AKT/mTOR pathway. Here, BRCA1 is linked to neoplasm.